uploads/2018/02/Remicade.png

Performance of Johnson & Johnson’s Remicade and Stelara in 2017

By

Updated

Remicade’s revenue trends

In fiscal 2017, Johnson & Johnson’s (JNJ) blockbuster drug Remicade generated revenues of $6.3 billion, which reflected an ~9.3% decline on a year-over-year (or YoY) basis. In 2017, in the US market and the international market, Remicade generated revenues of $4.5 billion and $1.2 billion, respectively, which reflected ~6.5% and 8.6% declines on a YoY basis.

In 4Q17, Remicade reported revenues of ~$1.5 billion, which is an ~9.7% decline YoY. In the US market and international markets, Remicade reported revenues of 1.1 billion and $278.0 million, respectively, in 4Q17. Increased discounts and competition for available biosimilars primarily contributed to the decline of Remicade’s revenues in 4Q17.

Article continues below advertisement

Stelara’s revenue trends

In fiscal 2017, Stelara generated revenues of ~$4.0 billion for ~24.0% growth on a YoY basis. In 2017, in the US and international markets, Stelara generated revenues of $2.8 billion and $1.2 billion, respectively, which reflected ~22.3% and ~28.4% growth YoY.

In 4Q17, Stelara reported revenues of ~$1.1 billion, which reflected ~23.0% growth on a YoY basis and a 4.0% decline quarter-over-quarter. In 4Q17, in the US and international markets, Stelara generated revenues of $740.0 million and $341.0 million, respectively, which is ~17.0% and ~38.0% growth on a YoY basis.

In 4Q17, the strong uptake of Stelara for the treatment of Crohn’s disease was primarily contributed to its high sales growth.

In the Crohn’s disease drugs market, Stelara’s peers include AbbVie’s (ABBV) Humira, Biogen’s (BIIB) Tysabri, and Takeda Pharmaceuticals’ (TKPYY) Entyvio.

Immunology segment’s performance

In 4Q17, Johnson & Johnson’s Immunology segment reported revenues of $3.1 billion, which reflected ~5.1% growth on a YoY basis. In 4Q17, JNJ’s Immunology segment generated net revenues of $2.2 billion and $859.0 million, respectively, which is ~3.2% and ~10.3% growth on a YoY basis.

In fiscal 2017, JNJ’s Immunology segment generated net revenues of ~$12.2 billion, which is ~2.3% growth on a YoY basis. The launch of Tremfya, solid growth of Stelara in 2017, and consistent growth of Simponi sales primarily contributed to the growth of JNJ’s Immunology business in 2017.

In the following article, we’ll discuss Simponi’s revenue trends in detail.

Advertisement

More From Market Realist